Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1326919 | 0.85 | SLC6A4 (0.45) | AOC3OPRL1OPRM1SLC6A4KDR | |
| SCHEMBL3587092 | 0.85 | OPRL1 (0.49) | AOC3OPRL1OPRM1SLC6A4KDR | |
| SCHEMBL493073 | 0.85 | AOC3 (0.41) | AOC3OPRL1OPRM1SLC6A4KDR | |
| SCHEMBL27876854 | 0.84 | OPRL1 (0.40) | AOC3OPRL1OPRM1SLC6A4KDR | |
| SCHEMBL492928 | 0.82 | AOC3 (0.39) | AOC3OPRL1OPRM1SLC6A4KDR | |
| SCHEMBL1328170 | 0.82 | OPRL1 (0.43) | AOC3OPRL1OPRM1SLC6A4KDR | |
| SCHEMBL494252 | 0.82 | OPRL1 (0.40) | AOC3OPRL1OPRM1SLC6A4KDR | |
| SCHEMBL1328154 | 0.82 | OPRL1 (0.42) | AOC3OPRL1OPRM1SLC6A4KDR | |
| SCHEMBL493690 | 0.81 | AOC3 (0.38) | AOC3SLC6A4SLC6A3SLC6A2IDO1 | |
| SCHEMBL492682 | 0.81 | OPRL1 (0.41) | AOC3OPRL1OPRM1SLC6A4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101384544-B | Substituted cyclohexylmethyl derivatives | GRUENENTHAL GMBH | 2014-01-22 | — | — | CN | claimed |
| US-8058475-B2 | Substituted cyclohexylmethyl compounds | GRUENENTHAL GMBH (DE) | 2011-11-15 | — | — | US | claimed |
| EP-1989174-B1 | SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-08-03 | — | — | EP | claimed |
| US-20090286833-A1 | Substituted Cyclohexylmethyl Compounds | GRUENENTHAL GMBH (DE) | 2009-11-19 | — | — | US | claimed |
| CN-101384544-A | Substituted cyclohexylmethyl derivatives | GRUENENTHAL GMBH (DE) | 2009-03-11 | — | — | CN | claimed |
| CN-101384544-B | Substituted cyclohexylmethyl derivatives | GRUENENTHAL GMBH | 2014-01-22 | — | — | CN | disclosed |
| US-8119633-B2 | N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-8058475-B2 | Substituted cyclohexylmethyl compounds | GRUENENTHAL GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| EP-2150530-B1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-10-26 | — | — | EP | disclosed |
| EP-1989174-B1 | SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2011-08-03 | — | — | EP | disclosed |
| EP-2150530-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| US-20090286833-A1 | Substituted Cyclohexylmethyl Compounds | GRUENENTHAL GMBH (DE) | 2009-11-19 | — | — | US | disclosed |
| CN-101384544-A | Substituted cyclohexylmethyl derivatives | GRUENENTHAL GMBH (DE) | 2009-03-11 | — | — | CN | disclosed |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| EP-1989174-A1 | SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008131947-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2007079930-A1 | SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | AOC3 3638/4885OPRL1 4/4885OPRM1 20/4885 |
| US-20090286833-A1 | Substituted Cyclohexylmethyl Compounds | CNR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R | AOC3 2137/4885OPRL1 238/4885OPRM1 57/4885 |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | SULT2A1, SULT1A1, SCN1A | AOC3 4794/4885OPRL1 26/4885OPRM1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.